Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers
Completed · Phase 1/Phase 2
Conditions studied: Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma, Unspecified Adult Solid Tumor, Protocol Specific
In brief
Phase II trial to study the effectiveness of combining imatinib mesylate with bevacizumab in treating patients who have advanced melanoma or other metastatic or unresectable cancer. Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Bevacizumab may stop the growth of tumor cells by stopping blood flow to the tumor. Combining imatinib mesylate with bevacizumab may kill more tumor cells
Key facts
- Study ID
- NCT00074308
- Run by
- National Cancer Institute (NCI)
- People needed
- 40
- Starts
- 2003-10-01
- Expected to finish
- 2009-07-01
- Last updated by the study team
- 2018-06-20
Who can join
Age: 21 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Histologically or cytologically confirmed diagnosis of 1 of the following:
- Metastatic or unresectable malignancy for which standard curative or palliative measures do not exist or are no longer effective (phase I) (phase I study closed to accrual as of 8/23/04)
- Melanoma (phase I and II)
- Measurable disease (phase II)
- No history or clinical evidence of CNS disease, including primary brain tumor or brain metastases
- Performance status - ECOG 0-1
- More than 3 months
- WBC at least 3,000/mm\^3
- Absolute granulocyte count at least 1,500/mm\^3
- Platelet count at least 100,000/mm\^3
- No history of bleeding diathesis or coagulopathy
- Bilirubin no greater than 1.5 times upper limit of normal (ULN)
- AST and ALT no greater than 2.5 times ULN
- INR no greater than 1.5
- APTT normal
- Creatinine no greater than 2.0 times ULN
- Creatinine clearance at least 40 mL/min
- No proteinuria
- Urinary protein less than 500 mg/24 hours
- No history of stroke
- No uncontrolled hypertension within the past 6 months
- Blood pressure less than 150/100 mm Hg on a stable antihypertensive regimen
- None of the following within the past 6 months:
- Myocardial infarction
- Unstable angina
Where it is running
- Abramson Cancer Center of The University of Pennsylvania — Philadelphia, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.